Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05168124
Other study ID # 2021-00671
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 8, 2023
Est. completion date July 2026

Study information

Verified date August 2023
Source University of Zurich
Contact Sarah Schiebler, MD
Phone 0041 255 52 80
Email sarah.schiebler@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a distinct disease entity with an estimated prevalence of 0.3-0.7% and more common in women (3:1 ratio). It can be diagnosed according to the Institute of Medicine (IOM) 2015 consensus definition using 3 major criteria and one of 2 minor criteria. Diagnosis requires that the patient have the following three symptoms: 1. A substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities that persists for more than 6 months and is accompanied by fatigue, which is often profound, is of new or definite onset (not lifelong), is not the result of ongoing excessive exertion, and is not substantially alleviated by rest, 2. Post-exertional malaise,* and 3. Unrefreshing sleep* At least one of the two following manifestations is also required: 1. Cognitive impairment* or 2. Orthostatic intolerance Note* Frequency and severity of symptoms should be assessed. The diagnosis of ME/CFS should be questioned if patients do not have these symptoms at least half of the time with moderate, substantial, or severe intensity. Currently, individually tailored therapy with emphasis on cognitive behavioral therapy and graduated activity therapy is considered the therapy of first choice, although their effectiveness has been critically questioned in recent years. There are often frustrating treatment courses, a larger proportion of partial remissions, a significantly smaller proportion of full remissions and return to work. The study aims to evaluate patients of the outpatient service for chronic fatigue at the Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Switzerland, in the context of a group therapy for the treatment of CFS/ME in respect to the response to different, non-drug based therapeutic procedures and to gain knowledge about the effects of the therapy. The study is a clinical comparative study of therapeutic procedures/interventions without the use of drugs or a medical product. The interventions are Acceptance Commitment Therapy (ACT) and Micro Breaks in Everyday Life (MBEL) adapted to CFS/ME. The collection of biological samples (saliva, blood) and health-related personal data (actigraphy, psychometric data from questionnaires) is associated with minimal risks and burdens.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date July 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Diagnosis for CFS/ME - Psychiatric clinical stability in the past 3 months: - No diagnostic change to other categories of the International Classification of Diseases (ICD-10) - No psychiatric inpatient treatments - No psychiatric emergency treatments - No suicide attempts - Possession of internet access - Sufficient skills to use electronic devices - The willingness to engage in the described therapeutic procedures or interventions (ACT, MBEL) Exclusion Criteria: - Insufficient knowledge of German - Severe psychiatric disorders (e.g. personality and posttraumatic stress disorders, dissociative and psychotic disorders, intelligence reduction, untreated attention deficit hyperactivity disorder) and acute suicidal tendencies - Untreated or severe internal medicine disorders e.g., thyroid dysfunction, central and obstructive sleep apnea syndrome (i.e., apnea-hypopnea index >15 and/or "high-risk group for obstructive sleep apnea" according to the Berlin Questionnaire) - Cardiovascular disease such as chronic heart failure - Severe or untreated neurological diseases (e.g. Parkinson's disease, dementia, restless legs syndrome, narcolepsy) - Alcohol and drug dependence - Initiation of psychopharmacotherapy at a dosage provided for guideline-appropriate treatment of a mental disorder according to the Drug Compendium in the past 3 months - Start of other psychotherapy procedures in the last 3 months - Other parallel therapy methods (e.g. acupuncture, qigong, osteopathy) - Somatic (sleep-disrupting) treatments, cortisone treatment, or radio-/chemotherapy in the last 6 months

Study Design


Intervention

Behavioral:
Acceptance Commitment Therapy for chronic fatigue
ACT was originally developed for the treatment of depression and anxiety. Recently, a single study investigated ACT as a therapeutic approach in CFS/ME and showed no negative effects on disease progression. ACT is characterized by acceptance- and mindfulness-based techniques, serves to promote acceptance and the development of new value goals, and can thereby open up new perspectives on life, which would be promising in terms of a reduction of symptom focus that seems to be a crucial effective factor for an improvement in exhaustion states. The intervention involves psychoeducation and teaching coping strategies for dealing with symptoms, most notably fatigue, postexertional malaise, unrestful sleep, cognitive decline, and orthostatic dysregulation. For this purpose, the therapy manual designed for anxiety disorders is adapted to the needs of patients with CFS, the exercises and worksheets that teach the acceptance- and mindfulness-based techniques are adapted to the symptoms.
Micro breaks in everyday life for chronic fatigue
In terms of break design in the work context, research in recent years has increasingly focused on so-called "micro breaks" (MB) - mini breaks of one to five minutes in length. Transferred to mini breaks in everyday life (MBEL), there have been found fundamentally positive effects in terms of performance, vitality and well-being, which could also have a positive impact on the clinical picture of CFS/ME. However, practically no research results are yet available with regard to the implementation of MB in everyday life of patients with CFS/ME. The effects of MB, on the other hand, have been tested several times in everyday work settings and showed desirable effects on mood, attention, fatigue, vitality, performance, and well-being.

Locations

Country Name City State
Switzerland University Hospital of Zurich Zürich

Sponsors (2)

Lead Sponsor Collaborator
Sarah Schiebler University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fatigue Severity Scale (FSS) The FSS comprises 9 questions, by answering which the patient can assess his limitations due to fatigue of the past week on a 7-point scale. The FSS is considered a well-established assessment tool for surveying subjective fatigue, the resulting limitations in daily, social, as well as occupational life and physical activities. Total score 36-52 is indicative of moderate fatigue ("mild/ no fatigue" at FSS total = 35, "moderate fatigue" at 36 = FSS total = 52), score greater than or equal to 53 is indicative of severe fatigue ("severe fatigue" at FSS total = 53). The entire duration of the study is 3 years.
See also
  Status Clinical Trial Phase
Recruiting NCT05899595 - Effects of a Personalized Physical Training to Reduce Fatigue N/A
Not yet recruiting NCT01154647 - Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes N/A
Completed NCT00375973 - Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome Phase 2/Phase 3
Completed NCT02499302 - Mental Training for CFS Following EBV Infection in Adolescents N/A
Completed NCT02156128 - Subjective Memory Complaints, Objective Memory Performance and Cognitive Training N/A
Not yet recruiting NCT06386133 - Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care N/A
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT04435002 - The Effect of Acupressure on Fatigue in Individuals With Chronic Fatigue Syndrome N/A
Recruiting NCT05778006 - Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (ME/CFS) Registry and Biobank, COVID-19, SARS-CoV-2
Recruiting NCT06253026 - Fatigue in Air Search and Rescue Missions
Completed NCT00001415 - Glucocorticoid Effects on Cellular Cytokine Release N/A
Completed NCT04797871 - Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19 N/A
Recruiting NCT04049331 - Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone Phase 2
Completed NCT02335437 - Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents N/A
Recruiting NCT05728918 - Effectiveness of Antrodia Cinnamomea Mycelia on Improving Immune Response in Subhealth People N/A
Completed NCT04833673 - The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial N/A
Recruiting NCT04947488 - Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital N/A
Recruiting NCT05840237 - REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID N/A
Active, not recruiting NCT04104750 - The Assessment of Fatigue and Quality of Life in Patients With Bone Tumor,